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Abstract 
 
The objective of this research was the evaluation and forensic validation of 
Denaturing High-Performance Liquid Chromatography (DHPLC) as a sequencing-
independent means of detecting the presence of sequence differences in pair-wise 
mixtures of non-concordant amplicons of human mitochondrial DNA (mtDNA). The 
reproducibility and efficacy of DHPLC results, including amplification reproducibility, 
injection reproducibility, and column-to-column reproducibility were measured, showing 
negligible assay-to-assay variability.  In addition, cross-contamination on the DHPLC 
columns demonstrated very low level DNA carryover between a high-abundance sample 
and subsequent zero-volume injections.  
The accuracy with which DHPLC technology can be used to screen both evidence 
and control samples in the context of a forensic laboratory was evaluated.  This was 
demonstrated by a number of pair-wise comparisons of each of the forensically relevant 
amplicons from 95 unrelated individuals in the study, and was in 100% agreement with 
sequencing data.  Thus, DHPLC can be used to detect a diversity of sequence differences 
(transitions, transversions, insertions and deletions) in the mtDNA D-loop. Accordingly, 
DHPLC may have utility as a presumptive indicator of mtDNA sequence concordance 
samples.  
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Chapter One: Introduction 
 
Mitochondrial DNA:  A Robust Genetic Marker 
Mitochondria are often referred to as the molecular powerhouse of the cell, as 
they are responsible for the majority of adenosine triphosphate (ATP) synthesis in the 
body.  In addition to supplying cellular energy, mitochondria are involved in a multitude 
of other processes, including cellular respiration, steroid synthesis, elongation of fatty 
acids, apoptosis, and heat production  (McBride et al., 2006).   
Mitochondria, present in almost all eukaryotic cells, were first discovered as 
distinct cytoplasmic organelles in 1840, and in 1963 it was determined that they in fact 
carry their own DNA  (Robin, and Wong, 1988; Mounolou and Lacroute, 2005).  
However, not all eukaryotic cells contain mitochondria, including such examples as 
Giardia intestinalis, Trachipleistophora hominis and Entamoeba histolytica.  Although 
these amitochondrial organisms lack actual mitochondria, they do appear to have 
remnants of mitochondria and mtDNA genes in their nuclear genome (Toval et al., 2003).  
The mitochondrial DNA (mtDNA) genome is a closed, circular, double-stranded 
molecule consisting of typically 16,569 base pairs. A reference mtDNA genome was 
completely sequenced by a team of scientists at the Cambridge Research Institute in 1981 
(Anderson et al., 1981).   The 1981 sequence was derived primarily from a placenta of a 
2 
European individual; however, some HeLa and bovine sequence was used to fill in gaps 
due to early sequencing procedural problems. The original placental material was 
reanalyzed by another group in 1999 (Andrews et al. 1999), which found 11 nucleotides 
that differed from the Anderson et al. (1981) sequence. This sequence was therefore 
termed the revised Cambridge Reference Sequence (rCRS) and is the current standard for 
comparison of mtDNA sequence variations.  The sequence within the genome can be 
broadly divided into either the coding region (about 15.5 kb, or 93% of the genome) and 
the non-coding control region (about 1.1 kb, or 7% of the genome).   
 The two strands of mtDNA differ significantly in their base composition.  The 
heavy strand (H-strand) is purine rich, having a greater number of guanine nucleotides, 
whereas the light strand (L-strand) is pyrimidine rich and thus physically lighter.  The 
sequence of the mtDNA genome codes for a total of 37 genes, all of which are essential 
for normal mitochondrial function.  A total of 28 gene products are found on the H-strand 
and 9 on the L-strand.  Of the 37 genes, 13 are for proteins which are necessary for 
cellular respiration, including the NADH dehydrogenase 6 enzyme, 22 are for 
mitochondrial transfer RNAs (tRNA) and the remaining two encode the 16S and 23S 
subunits of ribosomal RNA (rRNA) (McBride et al., 2006) (Figure 1). 
In contrast to a single copy of the diploid nuclear DNA genome, the majority of 
human cells contain from 200 to over 1,000 copies of the mtDNA genome depending on 
its host tissue’s specific energy demands ( Robin and Wong, 1988) (Frahm et al., 2005).  
This abundance of mtDNA makes it a particularly attractive target for forensic analysis 
because it can typically be amplified from a number of different tissues where nuclear 
DNA may be limiting or absent (e.g., hair shafts and aged or environmentally 
3 
compromised tissues such as skeletal remains).  For example, mtDNA has been used for 
the identification of skeletal remains from the Vietnam War (Holland et al., 1993), 
identification of bone material from a grave in Yekaterinburg, Russia belonging to Tsar 
Nicholas II (Ivanov et al., 1996), human remains identification following the September 
11, 2001 World Trade Center attack (Budimlija et al., 2003), the identification of shed 
hairs from a hat left behind at a robbery (Allen et al., 1998), and even in cases of sexual 
assault (Hatsch et al., 2007). 
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Figure 1:  The Human Mitochondrial DNA Genome 
The genes encoded by the mitochondrial DNA (mtDNA) genome are noted. Point 
mutations associated with mitochondrial diseases are documented in the center of the 
genome. Diagram provided by MitoMap (http://www.mitomap.org/).  
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Organization of the Mitochondrial DNA Genome 
The mitochondrial genome is much more efficiently organized than the nuclear 
DNA genome, containing very little non-coding sequence (7%) compared to the nuclear 
genome where approximately 97% is not expressed.  The 37 genes encoded by the 
mitochondrial genome are nearly contiguous with each other, lacking introns and only 
occasionally having one or two base non-coding sequences separating them.  Because of 
this protein coding sequence, there are relatively few sites at which variations in sequence 
can be tolerated. Therefore, mtDNA is considerably less polymorphic than its nuclear 
counterpart, despite its higher rate of mutation.   In fact, the only significant region of the 
genome that does not code for a gene product is the displacement loop region, also 
known as the D-loop.  This 1.1 kb stretch of often triplex DNA, known as the “control 
region”, contains essential regulatory functions, including the origin of replication for the 
generation of multigenic transcripts and DNA replication of the heavy strand.  Despite 
the limited amount of sites for tolerated sequence variations, the mitochondrial genome 
has been shown to have a mutation rate within the control region up to ten times that of 
comparable nuclear DNA sequences (Brown et al., 1979).  Forensic analysts are 
particularly interested in specific portions of this control region, designated hypervariable 
regions 1 (HV1) and 2 (HV2), because of their non-regulatory and non-protein-coding 
status and the dense array of sequence variability they exhibit within human populations.  
Some forensic laboratories also make use of the hypervariable 3 (HV3) region on 
occasions where increased discriminatory power is necessary.    
HV1 and HV2 regions span roughly positions 16024-16383 and 57-372, 
respectively, whereas the HV3 region spans positions 438-574 (numbered corresponding 
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to the rCRS (GenBank accession number NC_012920); (Andrews et al., 1999). Not only 
can there be single nucleotide mutations between individuals, but there are also two 
separate homopolymeric stretches of C nucleotides (poly-C repeats, or C-stretches) in 
both the HV1 and HV2 regions.  MITOMAP, an internet mitochondrial sequence 
database, maintains a list of published mtDNA polymorphisms found within the D-loop 
and forensically informative HV1 and HV2 regions (http://mitomap.org/bin/view.pl 
/MITOMAP/PolymorphismsControl).  As of April 2011, this list currently includes 1,013 
sites at which polymorphisms have been detected between the nucleotide positions 
16024-576 of the D-loop control region, most of which are associated with the HV1 and 
HV2 regions.  The majority of these polymorphisms consist of single base substitutions, 
although some insertions and deletions of sequence have also been also observed.  
Although many of these polymorphisms are extremely rare, or are only seen in specific 
ethnic populations, pairwise comparisons of mtDNA sequences of both hypervariable 
regions between maternally unrelated individuals usually reveal multiple sequence 
differences.   Based on a study of 1,393 unrelated individuals comprising eight 
population groups, most mtDNA sequence polymorphisms were observed only once 
within a particular population group. The highest amount of mtDNA sequence diversity 
was seen in African-American populations, where an average of 14.1 nucleotide 
differences was observed between individuals.  The lowest amount of diversity was seen 
within the Caucasian population, where only 8.4 nucleotide differences were observed 
(Budowle, et al., 1999).  In addition, there are a small number of common, shared 
HV1/HV2 haplotypes in the Caucasian database. The most common HV1/HV2 haplotype 
occurs at a frequency of about 7% in the population (Lutz-Bonengel et al., 2003). 
7 
Mitochondrial haplotypes can also be grouped into clusters based on evolutionary 
relatedness, which are defined by the presence of specific sequence polymorphisms in the 
mtDNA genome.  These clusters, known as haplogroups, are based on descent, described 
by a capital letter designation, and are the result of migrations of ancient human 
populations out of Africa thousands of years ago (Figure 2).  Continent-specific markers 
have been identified for Africans (Chen et al., 1995), Asians (Schurr et al., 1990), and 
European Caucasians (Torroni et al., 1994).  African mtDNAs can be classified into one 
of three main haplogroups (L1, L2 or L3). Haplogroup L1 is considered to be the earliest 
since it is found at the root of the human mtDNA lineage tree. The Eurasian haplogroups 
M and N are believed to have left Africa approximately 40,000 – 60,000 years ago to 
give rise to the current haplogroups in Asia (A, B, C, D, F, and G) and Europe (H, I, J, K, 
T, U, V, W, and X). 
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Figure 2: Human mtDNA Migration Patterns and Haplogroups 
Letters designate the names of specific haplogroups, based on published mtDNA 
sequence data. Arrows indicate the pattern of migration originating out of Africa. 
Diagram provided by MitoMap (http://www.mitomap.org/).   
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Mitochondrial DNA as a Forensic Tool 
Mitochondrial DNA has a number of characteristics which makes it an ideal 
choice for forensic use.  First, it has been estimated that the mtDNA genome evolves at a 
rate that is up to ten times that of its chromosomal counterpart (Brown et al., 1979).  This 
is an important factor when considering that data consistently show that unrelated 
individuals are extremely likely to have different mtDNA haplotypes thus making 
mtDNA useful for purposes of human identity testing.  This higher mutation rate can be 
accounted for by such factors as DNA repair inefficiencies, oxidative damage, and the 
greater number of replicate cycles that mtDNA undergoes during cell growth (Mambo et 
al., 2003).  Evidence also suggests that in spite of such an elevated mutation rate, the 
majority of mtDNA molecules within a given individual will still be represented by a 
single sequence (homoplasmy).  Occasionally, however, a de novo mutation may occur 
and propagate, resulting in the phenomenon known as heteroplasmy.  Heteroplasmy is a 
state in which two distinct mtDNA haplotypes coexist within a single individual. This is 
thought to be due to a mtDNA genome copy “bottleneck” during the early stages of 
oocyte development (Marchington et al., 1998).  The bottleneck theory purposes that the 
number of copies of mtDNA in each early oocyte is reduced to a small number of copies 
as compared to the mature oocyte. Thus, a small number of molecules are chosen as the 
founder population for all of the mtDNA molecules that are transmitted to the next 
generation.  This set of molecules could contain a homogenous population of mtDNA, or 
perhaps a heterogeneous mixture due to mutations.  Sometimes, such heteroplasmy may 
increase the discriminatory power of mtDNA identification by providing an additional 
inclusionary tool for the mitotype, such as situations where an evidentiary sample and a 
10 
reference sample both exhibit heteroplasmy at the same nucleotide.  Other times, it can 
lead to confusion when comparing two sequences that are assumed to be concordant, as it 
may be considered a mixture of mitotypes from more than one individual.    
Second, human mtDNA is thought to be almost completely maternally inherited 
(Giles et al., 1980).  This can be explained by the nearly 100,000 copies of the 
mitochondrial genome residing in the oocyte, and the fact that the few (possibly only two 
or three) mitochondria present in the spermatozoa are concentrated in the mid-piece and 
tail region, which are lost following fertilization. Additionally, if the sperm mitochondria 
do make it to the oocyte, they appear to be preferentially degraded.  Despite this maternal 
preference, some research has reported a few incidences known as “paternal leakage,” 
where some paternal inheritance of mtDNA and recombination has occurred. A single 
case of paternal co-inheritance of mtDNA in humans has been reported so far, in a male 
individual with a mitochondrial myopathy (Schwartz and Vissing, 2002; Bandelt et al., 
2005).  In addition, such paternal inheritance of mtDNA has been reported in species 
ranging from mussels to sheep (Stewart et al., 1995; Zhao et al., 2004).   Although 
paternal leakage may occur in rare instances, the normal detectable inheritance pattern of 
mtDNA is maternal.  This maternal inheritance pattern, barring multiple mutations, 
allows for forensic identifications to be made using reference samples from within the 
entire maternal lineage, including those that may be separated by several generations, 
when those of close relatives are no longer obtainable. 
Third, mtDNA is present in a high copy number within most cells.  It is estimated 
that a single cell may contain hundreds of mtDNA genomes for every copy of nuclear 
DNA (Robin and Wong, 1988).  Depending on the needs of the particular cell type, the 
11 
actual copy number present per cell can vary greatly among different tissue types.  For 
instance, there are more mitochondria in muscle and brain cells than in skin cells (Veltri 
et al., 1990). The general abundance of mtDNA can prove vital in situations where the 
amount of sample may be limited or its quality may be degraded, which is often the case 
in forensic DNA analyses.  Samples that are typical candidates for mtDNA analysis 
include aged bloodstains, skeletal remains, fingernails, teeth, and hair shafts lacking root 
tissue. The use of mtDNA typing of skeletal remains is often essential in cases of missing 
persons or in events such as mass disasters where small bone fragments may be the only 
remaining source of DNA available.  In addition, mtDNA testing of hair shafts is of 
particular importance because shed hairs are common sources of evidentiary material at 
crime scenes.  
 
Current Approaches to Forensic mtDNA Analysis 
In a forensic setting, human mtDNA is analyzed by direct comparison of DNA 
sequence data of the HV1 and HV2 regions to the rCRS (Andrews et al., 1999).  
Standardizing alignments of sequences with the rCRS and following consistent 
nomenclature for sequence differences is critical to avoid unintentionally describing two 
sequences as different when in they are actually the same.  In fact, several publications 
have dealt with the nomenclature of sequence data by establishing specific “rules” to 
follow when determining an mtDNA haplotype (Carracedo et al., 2000; Tully et al., 
2001; Wilson et al., 2002).  Briefly, differences are reported using the nucleotide 
positions and the particular base mutation.  For example, a sequence that is identical to 
the rCRS except for having a T instead of a C at position 16150 is designated as 16150T.  
12 
In the situation of length polymorphisms in the poly-C stretches, any extra Cs are added 
onto the end of the poly-C stretch.  The variant is named using a decimal notation to 
indicate the number of nucleotides that were in addition to the poly-C repeat in the rCRS.  
For example, if a particular mtDNA sequence has an additional C compared to the rCRS 
following the C-stretch of positions 303-315, it would be designated as 315.1C.  A 
similar nomenclature is used to describe insertions or deletions of nucleotides as 
compared to the rCRS.  For instance, if an additional T was inserted following position 
294, it would be designated as 294.1T.  Finally, deletions are the result of nucleotides that 
are missing as compared to the rCRS; an mtDNA sequence that was missing nucleotide 
325 would be named 325D.   
The general rules for naming profiles are as follows (Wilson et al., 2002): 
• Profiles should be characterized so that the least number of differences 
from the reference sequence are present.   
• If there is more than one way to maintain the same number of differences 
with respect to the reference sequence, differences should be prioritized as 
follows: 
1. insertions/deletions (indels) 
2. transitions (purine-to-purine or pyrimidine-to-pyrimidine changes) 
3. transversions (purine-to-pyrimidine or pyrimidine-to-purine 
changes) 
• Because all genes have a 5’ to 3’ direction of transcription and mtDNA 
genes are encoded on both the heavy and light strands of the closed 
circular molecule, insertions and deletions should be placed 3’ with 
respect to the light strand of human mtDNA.  
• Insertions and deletions should be combined in situations where the same 
number of differences from the reference sequence is maintained. 
13 
In order to determine a person’s mtDNA haplotype, total genomic DNA is 
extracted from the biological source material. The extracted DNA is then subjected to 
amplification of the HV1/HV2 regions (total of 608bp) using four primer pairs (Table 1).  
For the HV1 region, two primer pairs, L15997/H16236 and L16159/H16391, are used to 
amplify overlapping 278 and 271 base pair fragments designated HV1A and HV1B, 
respectively.  The HV2 region is amplified by primer pairs L048/H285 and L172/H408 
which typically yields overlapping products of 278 and 277 base pairs designated HV2A 
and HV2B, respectively (Figure 3). The “L” and “H” designation refers to the light and 
heavy strand of the mtDNA genome from which the primer sequence is derived and the 
number indicates the corresponding position of the 3’ end of the primer with respect to 
the rCRS  (Anderson et al., 1981; Budowle et al., 2000). 
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Table 1:  Human mtDNA Primer Pairs 
The forensically-validated primers used for control region amplification of human 
mtDNA. 
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Figure 3:  HV1 and HV2 Primer Overlap Scheme 
The D-loop region of the mitochondrial genome is divided into two main 
fragments (HV1 and HV2).  For universal forensic amplification and sequencing, each 
fragment is divided into two smaller overlapping fragments (HV1A, HV1B, HV2A and 
HV2B).  See Table 1 for primer sequence information. 
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Once the overlapping products are amplified, they are sequenced using the 
dideoxy chain termination method, i.e., the Sanger method (Sanger et al., 1977). The 
Sanger method allows for differential fluorescent labeling of chain terminator ddNTPs. 
This allows single reaction sequencing where each label emits fluorescence at a different 
wavelength.  In this method, DNA templates are denatured and new strands of DNA are 
synthesized by Taq polymerase.  The incorporation of dideoxyribonucleotides creates 
populations of strands that are terminated with a fluorescent tag at all possible base 
positions along the template strand. This makes it possible to unambiguously identify the 
final base of each amplified mtDNA fragment. The resulting sequence product (i.e. pool 
of mtDNA fragments) is then fractionated by capillary electrophoresis (CE) using such 
commercial systems as the ABI Prism® 310, 3100, or 3130 Genetic Analyzer (Applied 
Biosystems, Foster City, CA).  In CE, the terminated DNA chains are subjected to an 
electric field that separates the amplified fragments based on their size.  The amplified 
products must be separated in order to determine the specific order of incorporated 
nucleotides across a target sequence.  A laser excites the fluorescent dye terminators as 
they pass a fixed transparent window in the capillary.   Light emitted by the excited 
fluorophores is then detected by a CCD camera.  The different bases are ultimately 
represented as colored peaks on an electropherogram. Next, the data from each individual 
sequence reaction are parsed to data analysis software, such as Sequencher® (Gene Codes 
Corp, Ann Arbor, MI) for sequence alignment and examination by an mtDNA analyst.   
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Denaturing High Performance Liquid Chromatography 
Analysis of mtDNA in a forensic casework context is labor intensive, expensive, 
and requires the expertise of skilled analysts currently employed by only a small number 
of public and private laboratories.  Efforts are ongoing to bring about a more streamlined, 
efficient, and more cost effective flow of the mtDNA analysis process.  A novel scheme 
to help accomplish these goals includes the development of a rapid and reliable screening 
technique for determining concordance/non-concordance between mtDNA samples prior 
to the laborious process of sequence analysis.   
Several different techniques to increase efficiency have been explored in recent 
years. These include hybridization to linear arrays of sequence-specific oligonucleotides 
(SSO) (Reynolds et al., 2000); denaturing gradient gel electrophoresis (DGGE); 
(Hanekamp et al., 1996); (Steighner et al., 1999); single-strand conformational 
polymorphism (SSCP) analysis (Alonso et al., 1996); (Barros et al., 1997); time-of-flight 
mass spectrometry (Butler and  Becker, 2001); and microarray-based analysis 
(Fukushima, 1999). While somewhat economical, these methods all have significant 
limitations, most importantly the fact that they often consume limited forensic evidence 
while not necessarily providing a more thorough, efficient evaluation of sequence 
differences across a pool of amplicons. 
Denaturing High-Performance Liquid Chromatography (DHPLC), on the other 
hand, helps resolve these issues by making it possible to accurately determine whether 
two mtDNA sequences are concordant or non-concordant. This can be done in a rapid, 
accurate, cost-effective, and automated approach.  Used for many years in the medical 
research and diagnostics fields, DHPLC has been employed to screen for a wide variety 
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of genetic mutations.  Based on the high-resolution chromatographic separation of DNA 
molecules that differ in sequence, even when they are identical in length, DHPLC has 
become the mainstay for rapidly determining whether the sequence of a test sample is 
identical to or different from a known reference sample (Rossetti et al., 2002); (Troudi et 
al., 2007). 
The fundamental principle behind DHPLC is Temperature Modulated 
Heteroduplex Analysis where an unknown DNA sequence to be analyzed is mixed with a 
known (reference) DNA sample. The mixture is then heat denatured.  Upon slow 
renaturation, a combination of homoduplices and heteroduplices are produced.  The 
homoduplices represent the original components of the mixture while the heteroduplices 
are formed as a result of the cross-hybridization between the different mixture 
components (Hou and Zhang, 2000).  DHPLC allows for the chromatographic separation 
of the homoduplices and heteroduplices as a function of their interaction with a 
proprietary DNASep® column.  In this process, triethyl ammonium acetate acts as an ion 
pairing reagent between the negatively charged DNA backbone and the alkylated 
poly(styrene-divinylbenzene) particles that comprise the resin of the DNASep® column.  
Using partially denaturing temperature conditions and an increasing acetonitrile gradient, 
it is expected that DNA homoduplices and heteroduplices will be individually eluted 
from the column.   Subtle differences between sequences, therefore, should be readily 
indicated by the appearance of distinct peaks on a chromatogram. Specifically, the 
earliest eluting peak (i.e., the peak with the shortest retention time) should represent the 
heteroduplex with the most destabilizing nucleotide mismatch. The latest eluting peak, by 
contrast, should have the most stabilizing basepair at the same position (Figure 4).  Only 
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when the unknown sample and the known reference sample are an exact match should a 
single homoduplex peak appear.  The resolution and specific retention times of the 
individual homo- and heteroduplex peaks is dependent upon the base composition of the 
amplicons which are being separated. Ideally, this should result in a unique DHPLC 
profile that allows the identification of concordance or non-concordance between 
samples.   
In addition, DHPLC is easily automated, which allows for rapid detection paired 
with high specificity.  Using a commercially available DHPLC system (WAVE® 3500 
Nucleic Acid Fragment Analysis System, Transgenomic Inc., Omaha, NE), a trained user 
can determine the presence of one or more nucleotide polymorphisms in any one of the 
four forensically validated HV1/HV2 amplicons in as little as seven minutes.  
Furthermore, these samples can be physically collected and purified following DHPLC 
analysis and then used directly for downstream sequence analysis.   
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Figure 4:  DHPLC Chromatogram of a mtDNA Mixture 
Illustration of the chromatographic separation of the hetero- and homoduplices 
created by cross-hybridization of two amplification products which differ in sequence by 
a single base. 
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Validation of DHPLC for use in Forensic Laboratories 
In order for a novel method or technique to be implemented in a forensic 
laboratory, it must undergo a rigorous validation process.  In July 2004, the Scientific 
Working Group on DNA Analysis Methods (SWGDAM) outlined the necessary steps to 
be taken during developmental research (Forensic Science Communications, 2004).  
These studies, which include accuracy, precision, and reproducibility, must show that the 
technique is reliable prior to use in forensic casework.  In 2009, The Quality Assurance 
Standards for Forensic DNA Testing Laboratories document was updated, 
(http://www.fbi.gov/about-us/lab/codis/qas_testlabs), though the central requirements for 
validation studies remained unchanged. 
The experiments presented in this thesis were designed to test the efficacy and 
reliability of DHPLC as a means of screening and/or comparative sequence analysis for 
the HV1 and HV2 regions of human mtDNA in forensic casework.  Specific studies 
include accuracy, precision, and reproducibility of assay results using a broad range of 
samples consistent with those typically seen in the forensic laboratory. In addition, cross-
contamination and assay detection sensitivity were also investigated.  This technology is 
readily available, and if validated successfully, will help streamline the laborious process 
of mtDNA analysis; thereby significantly contributing to the improvement of public 
safety and human identification efforts. 
 
 
 22 
Hypotheses and Objectives 
1. It is hypothesized that developmental validation of DHPLC will 
support its use as a tool for rapid and accurate comparative 
mtDNA sequence analysis.  This will make it possible to rapidly 
and cost effectively identify putative matches between questioned 
and known samples without laborious DNA sequencing. 
2. It is hypothesized that the developmental validation of DHPLC 
will allow it to act as a tool for identifying minor source 
components from mixed DNA samples.  This will facilitate the 
analysis of samples that yield low quality data when analyzed 
using current methods. 
3. It is hypothesized that implementation of DHPLC analysis of 
mtDNA reference and evidentiary samples for casework will make 
it possible for forensic laboratories to obtain potentially useful 
genetic data from samples that would not otherwise be amenable to 
analysis.   
In order to test the aforementioned hypotheses, the current study encompassed 
four major objectives. These were to: 
1. Evaluate the reproducibility of DHPLC results, including 
amplification reproducibility, injection reproducibility, and 
column-to-column reproducibility. 
2. Evaluate the degree of cross-contamination (if any) that may occur 
when using DHPLC technology.  This will be determined by 
capturing the elute of DNA-free injections following the injection 
of PCR amplified samples.   
3. Evaluate the accuracy with which DHPLC technology can be used 
to screen both evidence and control samples in the context of a 
forensic laboratory.  This will be demonstrated by a number of 
pair-wise comparisons of each of the forensically relevant 
amplicons from the 95 individuals in the study. 
4. Evaluate the ability of DHPLC to accurately detect a mixture of 
haplotypes, including heteroplasmy, within a single sample.  This 
will be achieved by pair-wise comparisons of samples included in 
a Proficiency Test with a known mixture purchased from a 
commercial supplier. 
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Chapter 2:  Materials and Methods 
 
Sample Collection and Avoidance of Contamination 
This research was conducted in compliance with U.S. Federal Policy for the 
Protection of Human Subjects (56 FR 28003),  and all protocols and human subject 
participation was reviewed and approved by the University of Denver’s Institutional 
Review Board for research involving human subjects.  Blood, buccal, and hair samples 
were collected from 103 unrelated subjects who had provided informed consent.  The 
blood samples were collected by a finger prick using sterile disposable medical lancets 
(Bayer Fingerstix™), buccal swabs taken by swabbing the inner cheek with sterile cotton 
swabs, and head hairs individually pulled by the subjects themselves.  A variety of bone 
samples, including femur, tibia, ribs, and skull fragments, were kindly provided by the 
Department of Anthropology at the University of Montana.  All samples were handled 
carefully in order to prevent sample-to-sample contamination or extraneous DNA 
contamination, and were stored at -20°C until DNA extraction.   
 
Mitochondrial DNA Extraction from Blood Stains and Buccal Swabs 
 
Mitochondrial DNA was extracted from both blood stains and buccal swabs using 
the EZ1 DNA tissue kit on the Qiagen BioRobot EZ1 DNA extraction robot (Qiagen Inc., 
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Valencia, CA) according to the manufacturer’s protocol as described below.  First, 
samples were cut under sterile conditions, placed into 1.7 ml tubes, and lysed with 190 µl 
of Qiagen’s G2 Buffer and 10 µl Qiagen proteinase K.  The samples were incubated at 
56°C for 15 minutes in a shaker incubator.  Following digestion, the samples were 
transferred to a 2 ml sample tube provided with the EZ1 tissue kit, discarding any solid 
material.  The EZ1 DNA Forensic Card contains two protocols: “1” for reference 
samples, and “2” for trace samples. The trace sample protocol is used when low yields 
are expected (less than 2.5 µg DNA; though the protocol can yield up to 5 µg), while the 
reference sample protocol is used when higher yields are expected (more than 2.5 µg 
DNA; though the protocol will also permit isolation of lower amounts of DNA).  For 
blood and buccal swabs, the reference sample protocol was used to isolate and purify the 
DNA. Samples were eluted using 200 µl of nuclease free water and the DNA was stored 
at -20°C until PCR amplification. 
 
Mitochondrial DNA Extraction from Hairs 
 
Approximately 2 cm of hair, including root tissue when available, was cut and 
placed in a 1.5 ml tube. In order to remove potential surface contamination, hair 
fragments were vigorously rinsed with 5% Tergazyme detergent, (Alconox, Inc., White 
Plains, NY) followed by multiple ultrapure water washes (18.2 MΩ·cm resistivity at 25 
°C and < 10 ppb Total Organic Carbon) and a final 100% laboratory grade ethanol rinse.  
Mitochondrial DNA was extracted from hairs using the EZ1 DNA tissue kit on the 
Qiagen BioRobot EZ1 DNA extraction robot (Qiagen Inc., Valencia, CA) as described 
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above, with the addition of the manufacturer’s “pretreatment for hair” protocol prior to 
extraction.  Briefly, the hairs were transferred to an EZ1 2 ml sample tube, and 180 µl of 
Buffer G2 and 10 µl Qiagen proteinase K was added to each sample and vortexed.  
Samples were incubated for 6 hours to overnight at 56°C in a shaker in order to dissolve 
the hairs and lyse the cells.  An additional 10 µl Qiagen proteinase K was added to each 
sample, mixed thoroughly, and incubated for 2 hours at 56°C.  For hair samples, the 
EZ1’s trace protocol was used to isolate and purify the DNA.  Samples were eluted using 
50 µl of nuclease free water and the DNA was stored at -20°C until PCR amplification. 
 
Mitochondrial DNA Extraction from Bone 
 
In order to remove surface contaminates from the bone samples, approximately 1-
2 g of bone was placed in a 5% Tergazyme solution and sonicated for 30 minutes. This 
was repeated twice using fresh 5% Tergazyme, followed by a water and ethanol rinse, 
respectively. The bone samples were then allowed to dry for a few hours in the extraction 
hood.  Pulverization of the bone samples was performed using the 6850 Freezer/Mill 
(SPEX SamplePrep, Metuchen, NJ) according to the manufacturer’s protocol.  Briefly, a 
small section of each bone was added to the provided freezer mill sample vials, along 
with a provided steel rod, and placed into the freezer mill coil.  Liquid nitrogen was 
added to the tub of the freezer mill, in order to aid in grinding the bone samples.  The 
freezer mill incorporates the use of a high-speed electromagnet to drive the steel rod back 
and forth inside the vials, thereby pulverizing the samples.  Finally, DNA was extracted 
from approximately 200 mg of pulverized bone powder using the EZ1 DNA tissue kit on 
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the Qiagen BioRobot EZ1 DNA extraction robot (Qiagen Inc., Valencia, CA) according 
to the manufacturer’s “pretreatment for bones or teeth” protocol.  This included placing 
the bone powder into a 2 ml tube and adding 600 μl 0.5 M EDTA (pH 8.3) to aid in 
decalcification of the bone.  The samples were incubated in a shaker at 37°C for 24–48 
hours.  Following the incubation, 20 μl of Qiagen Proteinase K was added, and incubated 
again at 56°C for approximately 3 hours. The samples were then centrifuged at 10,000 x 
g for 4 minutes, and 200 μl of the supernatant was transferred to an EZ1 sample tube.  
For bone samples, the EZ1’s trace protocol was used to isolate and purify the DNA. 
Samples were eluted using 200 µl of nuclease free water and the DNA was stored at -
20°C until PCR amplification. 
 
Mitochondrial DNA Amplification of HV1 and HV2 Regions 
Standard, forensically-validated PCR primers were used to amplify four 
forensically-relevant regions (HV1A: 278bp; HV1B: 271bp; HV2A: 278bp; HV2B: 
277bp) of the human mitochondrial genome (Table 1) in a 50 µl  reaction, with primers at 
final concentration of 1 μmol/L; 2.25 U of AmpliTaq GOLD® DNA polymerase (Applied 
Biosystems, Foster City, CA), supplemented with 0.25U Pfu DNA polymerase 
(Stratagene, La Jolla, CA)), and 200 μmol/L of each dNTP (Stratagene) with 10 μl 
(approximately 0.1-1 ng) of DNA extract. Amplifications were carried out on a 
GeneAmp® 9700 Thermal cycler (9600 emulation mode); (Applied Biosystems) using a 
thermal profile consisting of denaturation at 95˚C for 10 minutes, followed by 32 cycles 
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of denaturation at 95˚C for 20 seconds, primer annealing at 60˚C for 30 seconds and 
extension at 72˚C for 45 seconds, followed by a final extension at 72˚C for 15 minutes.  
 
PCR Amplification and Yield Determination for mtDNA using DHPLC 
In order to confirm that the amplification reactions worked as expected and to 
determine the amplification yield, 7 μl of amplified sample was transferred to a sterile 0.2 
ml microcentrifuge tube and placed on the sample plate of the WAVE® 3500HT DNA 
Fragment Analysis System (Transgenomic Inc., Omaha, NE).  The PCR amplification 
and yield was then determined from analysis of 5 μl aliquots of each sample using a 
proprietary DNASep® analytical column and triethylammonium acetate (TEAA) pH 7.0 
at a final concentration of 0.1M as an ion-pairing reagent. The assay employed the DS 
Single Fragment Application (non-denaturing conditions, 0.9ml/min flow rate, oven 
temperature set at 50˚C) appropriate for the size fragment being assayed (HV1A: 278bp; 
HV1B: 271bp; HV2A: 278bp; HV2B: 277bp).  Eluting DNA peaks were detected by UV 
absorbance (260 nm).  Using the non-denaturing conditions amplified homoplasmic 
mtDNA typically elutes as a single peak in the chromatographic profile. 
 Based on previous experiments in our laboratory using a DNA sizing and 
concentration ladder, it was determined that the efficiency of the PCR and the amount of 
DNA present in a sample can be accurately determined from the area of the PCR 
amplicon peak.  Amplified DNA was estimated from the equation y=1230.9x + 712.99, 
where x is the DHPLC peak area and y is the DNA concentration (Figure 5).  
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Figure 5:  Standard curve of DNA concentration as determined from peak area of the 
PCR amplicon peak 
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Quantification of mtDNA using RT-PCR 
 
 The mitochondrial DNA Quantification protocol was adapted from 
Andreasson et al. (2002), and was designed to quantify the total amount of amplifiable 
human mtDNA in a sample to determine if sufficient human mtDNA was present to 
proceed with DHPLC and mtDNA sequencing analyses. The quantification assay used a 
primer and probe combination developed based on Andreasson et al. (Figure 6), along 
with the TaqMan® Universal PCR Master Mix (Applied Biosystems).  The RT-PCR 
reaction made use of the 5´ nuclease activity of AmpliTaq Gold® DNA polymerase to 
cleave a TaqMan® probe during PCR. The TaqMan® probe contains a reporter dye at the 
5´ end of the probe and a quencher dye at the 3´ end of the probe. During the reaction, 
cleavage of the probe separated the reporter dye from the quencher dye, which resulted in 
detectible fluorescence of the reporter.  The accumulation of PCR products therefore 
results in an increase in fluorescence.  The quantity of DNA in a sample was determined 
by monitoring the increase in fluorescence of the reporter dye, and compared to that of a 
known standard DNA curve.  For each PCR reaction in this study, 8 µl total of TaqMan® 
Master Mix (including primers and probe) were added to a 96-well optical plate, along 
with 2 µl of sample (Figure 7).  A total of 8 standards (106 – 101 copies/µl created by 
1:10 serial dilutions) were prepared from a purified master standard stock (216,227,941 
copies/ µl, quantified by UV spectroscopy) and added to the 96-well optical plate.  These 
standards served as the basis for a DNA quantification curve.  Real-Time PCR analysis 
was performed on an ABI PRISM® 7900HT Sequence Detection System (Applied 
Biosytems). 
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mtDNA RT- PCR Amplicon (143 bp) 
 
CCACTGTAAAGCTAACTTAGCATTAACCTTTTAAGTTAAAGATT
AAGAGAACCAACACCTCTTTACAGTGAAATGCCCCAACTAAAT
ACTACCGTATGGCCCACCATAATTACCCCCATACTCCTTACACT
ATTCCTCATCAC 
 
 
Primers and Probe 
 
mt-8294F (CCACTGTAAAGCTAACTTAGCATTAACC) @ 100umol/L (55.9°C) 
 
mt-8436R (CCATACTCCTTACACTATTCCTCATCAC) @ 100umol/L (56.2°C) 
 
 
mt-8345 (VIC-CCAACACCTCTTTACAGTGAAATGCCCCA-TAMRA) 
 
 
 
Figure 6:  Primer and probe sequences for Real-Time PCR quantification of mtDNA.  
VIC is the fluorescent reporter dye of the probe at the 5’ end of the sequence.  TAMRA is 
the quencher dye on the 3’ end of the probe. 
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Figure 7:  Reaction mix components for mtDNA quantification using the protocol 
adapted from Andreasson et al. (2002).  A total of 8 µl master mix was added to 2 µl 
DNA for each quantification reaction.  
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Cross-Hybridization Control Assay by DHPLC 
 
In order to determine whether or not the individual samples were homoplasmic or 
heteroplasmic prior to the mixing of different mitotypes, 7 μl of each amplicon was 
transferred to a sterile 0.2 ml microcentrifuge tube and cross-hybridized to itself by 
heating to 95°C for 4 min and then gradually cooling over a period of 45 minutes (1.5°C 
decrease/min) on an MJ Research, Inc PTC-100™ Thermal cycler or on an ABI 9700 
Thermal cycler (9600 emulation mode).  The self-hybridized samples were then removed 
from the thermal cycler and placed on the sample plate of the WAVE® autosampler.  The 
cross-hybridization control assay was carried out by DHPLC using the Mutation 
Detection Application (i.e., partially denaturing conditions, 0.9ml/min flow rate) and the 
appropriate standard fragment analysis method where oven temperature settings were 
dependent upon previous optimization studies performed by the laboratory (HV1A, 58°C; 
HV1B, 59.2°C; HV2A, 56.5°C or HV2B, 57°C). 
 
Purification of Amplicons using DHPLC 
 In order to clean up PCR amplified DNA for sequencing, the remaining 
reaction volume was loaded onto the WAVE® autosampler plate.  The DS Single 
Fragment Application for the appropriate size fragment (HV1A: 278bp; HV1B: 271bp; 
HV2A: 278bp; HV2B: 277bp) was selected and the “Fragment Collection” tab of the 
instrument’s Navigator™ software was used to generate a fraction collection method for 
PCR product purification.  A total of 20 μl of sample was injected and the eluted DNA 
fragments were then collected into 12 wells of a 96-well plate using the WAVE® 
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automated fragment collector.  Finally, these were combined into a single 0.6 ml 
microcentrifuge tube for further downstream analysis. Any unpurified DNA remaining on 
the WAVE® autosampler plate was stored at -20°C. 
 
Sequencing of Mitochondrial DNA using the ABI Prism® 310 Genetic Analyzer 
Following DHPLC purification and subsequent collection of the amplified DNA 
using the automated fragment collector, DNA samples were loaded into the CentriVap® 
Centrifugal Concentrator (Labconco, Kansas City, MO) for solvent evaporation.  
Concentrated samples were then reconstituted in 12 µl of ultrapure water.  DNA was 
labeled for dideoxy terminator sequencing (Sanger et al., 1977) using the BigDye 
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems).  Sequencing reactions were 
primed using the same PCR primers employed for amplification.  Samples were prepared 
in 10 µl reactions (2 µl  master mix, 1 µl  primer, 1 µl  5X sequencing buffer) and 
approximately 0.8-1ng (2 µl ) of amplified DNA. Labeling reactions were carried out on 
a GeneAmp® 9700 Thermal cycler (Applied Biosystems) using a thermal profile 
consisting of denaturation at 96˚C for 1 minute, followed by 25 cycles of denaturation at 
96˚C for 10 seconds, primer annealing at 50˚C for 5 seconds and extension at 60˚C for 2 
minutes.  
 Labeled products were purified on Performa® DTR V3 96-Well Short Plates 
(Edge BioSystems, Gaithersburg, MD) according to the manufacturer’s protocol.  Briefly, 
the plates were centrifuged at 850 RCF for 3 minutes in order to elute the storage buffer.  
Sample reactions were then pipetted directly into the center of the individual wells, and 
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centrifuged again at 850 RCF.  The eluate was retained, which contained the purified 
sequence labeling reaction products.  The labeled products were then resolved on an ABI 
PRISM® 310 Genetic Analyzer (Applied Biosystems) according to the manufacturer’s 
protocols.  Here, 2 µl of purified labeled products was added to 10 µl Hi-Di formamide 
(Applied Biosystems) and denatured in a GeneAmp® 9700 Thermal cycler (Applied 
Biosystems) at 95˚C for 2 minutes.  The plates were then snap-cooled for 2 minutes in a 
96-well ice plate.   
For electrophoresis, the plates were placed onto the ABI 310 Genetic Analyzer, 
using the POP-6™ polymer and 47cm x 50µm capillaries (Applied Biosystems). The raw 
electrophoretic traces were analyzed using the KB Basecaller software (Applied 
Biosystems) together with the appropriate dye set mobility file for the v1.1 kit using 
Sequencing Analysis Software v.5.1.1 (Applied Biosystems). The resulting sequence data 
were aligned using the Sequencher™ DNA analysis software (Gene Codes Corp, Ann 
Arbor, MI).  Appropriate positive and negative controls were included at all stages of the 
process.  
 
 DHPLC-Based Temperature-Modulated Heteroduplex Analysis (TMHA) 
Once DNA concentrations were determined on the basis of the peak area for each 
of the amplicons obtained during the PCR amplification and yield determination assay, 
the concentration of each of the PCR product tubes were normalized either by vacuum 
centrifugation or by dilution with ultrapure water to a final concentration of 4-5 ng/μl.   
Samples were then combined at a 1:1 molar ratio to generate a series of pair-wise 
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mixtures from individuals with different mtDNA haplotypes. The haplotypes for each 
sample had been determined previously by direct sequence analysis. 
The cross-hybridized mixtures were analyzed by TMHA (Kuklin et al., 1997) on 
the WAVE® System using a DNASep® analytical column and TEAA (0.1M final 
concentration; pH 7.0) as an ion-pairing reagent. Cross-hybridized mixtures were 
analyzed under partially denaturing conditions at the empirically determined optimal 
temperatures for each of the four mtDNA amplicons as previously described. The optimal 
acetonitrile linear gradient generated from differential mixing of buffer A (0.1M TEAA) 
and buffer B (0.1M TEAA, 25% ACN) required a 56% to 65% buffer B increase in 3.5 
minutes for the analysis of HV1A, HV2A and HV2B and a 55% to 64% buffer B increase 
in 3.5 minutes for HV1B. All samples were eluted at a 0.9ml/min flow rate and DNA 
peaks were detected by UV absorbance at 260nm. Standard DHPLC controls included: 
zero-volume injections to screen for DNA carryover between assays; no-template PCR 
controls to check for reagent contamination; and manufacturer mutation control standards 
to ensure rigorous buffer and DNASep® column quality control.  
The resulting chromatograms were visually examined. The presence of a single 
homoduplex peak was scored as consistent with sequence identity. The presence of more 
than one chromatographic peak or a distinct shoulder on a homoduplex peak was scored 
as consistent with the presence of one or more sequence differences between the two 
amplicons in the sample being assayed, i.e., sequence non-identity (O'Donovan et al., 
1998; Hou et al., 2000); (Figure 8).   
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Figure 8:  Example chromatograms of two samples cross-hybridized and analyzed on the 
DHPLC.  A single homoduplex peak indicates sequence identity (A) whereas multiple 
peaks indicate sequence non-identity (B).  The initial primer/nucleotide peak, dissolved 
oxygen peak, and final solvent wash peak are also indicated.  
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Sample-to-Sample Non-Carryover Validation Assays 
To confirm that there was no cross-contamination between subsequent injections 
from adjacent wells on the WAVE® autosampler plate, an amplified mtDNA sample was 
purified on the WAVE® system along with zero volume injections (to show there was no 
sample remaining on the column) and adjacent blank well injections (to show that there 
was no cross contamination between samples on the injection plate).  To accomplish this, 
the HV2A region (278bp) of a single mtDNA sample was amplified using the parameters 
previously described and injected under non-denaturing conditions.  Injections consisted 
of 20 µl sample, a zero volume injection, and 20 µl dH2O, followed by another sequence 
of 40 and 60 µl injections of sample.  The presence of a visually detectable peak between 
approximately 2 and 6.5 minutes was considered to be evidence of contamination.  The 
typical dissolved oxygen peak that appears at approximately 3.5 minutes was 
disregarded. 
 
DHPLC Amplification Reproducibility Validation Assays 
In order to assess the reproducibility of DHPLC-detected amplification, buccal 
swab samples from eight maternally-unrelated individuals were chosen based on 
sequence differences and extracted as described above.  The amount of mtDNA present 
in each extract was quantified by real-time PCR on the ABI 7900HT Real-Time PCR 
System (Applied Biosystems), and sample concentrations were normalized with ultrapure 
water to 40,000 copies/μl (Table 2).  Pair-wise mixtures representing each of the four 
forensically relevant mtDNA amplicons (HV1A, HV1B, HV2A, and HV2B) were then 
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created at a 1:1 molar ratio. These were then amplified in ten replicate 20 μl PCR 
reactions.  The resulting PCR products were cross hybridized and sequentially assayed 
under partially denaturing conditions (10 μl injections) using DHPLC.  In order to 
determine amplification reproducibility, the relative peak heights and elution peak 
retention times from each of the ten injections were averaged and the standard deviation 
determined.  
 
DHPLC Injection-to-Injection Reproducibility Validation Assays 
To assess the reproducibility of independent DHPLC injections, identical 
amplification products were assayed.  The same eight DNA extractions that were used for 
the amplification reproducibility experiments described in the preceding section were 
used to prepare pair-wise 1:1 molar ratio mixtures representing each of the four 
forensically-relevant mtDNA amplicons.  For each mixture, ten replicate 20 μl PCR 
reactions were prepared.  Following amplification, each reaction was cross-hybridized 
and identical reactions were combined into a single 0.2 ml tube for a total of 200 μl of 
amplified and cross-hybridized sample.  Each pooled sample (one pair-wise mixture 
representing each of four amplified mtDNA amplicons) was sequentially injected ten 
times (10 μl/injections) under partially denaturing conditions by DHPLC. In order to 
determine injection reproducibility, the relative peak heights and elution peak retention 
times from each of the ten injections were averaged and the standard deviation 
determined. 
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DHPLC Column-to-Column Reproducibility Validation Assays 
The reproducibility of injections between different DNASep® columns was 
assessed by comparison of ten two-component mixtures sequentially injected onto ten 
different DNASep® columns.  To do this, a total of ten pair-wise mixtures (representing 
both the HV2A and HV2B regions) were created at a 1:1 molar ratio from 20 maternally-
unrelated individuals and amplified using the PCR thermal profile described above.  
Master 400 μl PCR mixtures were set up from which 50 µl aliquots were transferred into 
eight 0.2 ml tubes for greater amplification efficiency.  Following amplification, each 50 
µl reaction was cross-hybridized and then pooled into a single 0.6 ml tube.  For 
subsequent DHPLC analysis, 10 µl of each mixture were injected under partially 
denaturing conditions, with columns being changed between each set of the ten 
injections.  To determine the reproducibility of different individual columns, the profile 
consistency and elution peak retention times from each of the ten injections were 
averaged and the standard deviation determined. 
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Table 2:  DNA sample normalization strategy for amplification and injection 
reproducibility experiments.  Samples were normalized and mixed at a 1:1 molar ratio 
prior to amplification. 
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Validation Using Proficiency Tests 
A commercial DNA mixture proficiency test was obtained from Orchid Cellmark 
(Dayton, OH) in order to determine whether DHPLC can accurately perform comparative 
sequence analysis as a means of efficiently screening and detecting the presence of 
mtDNA mixtures.  Such proficiency tests are largely used in forensic laboratories, and 
can be a useful model for testing the ability of DHPLC to detect sequence non-identity 
between two samples.   
The test kits contained a total of five samples. These included two forensic “i.e., 
unknowns” (including one mixture) and three reference samples “i.e., knowns.” All 
samples were extracted as described above, and a total of four amplicons were amplified 
from each sample using forensically validated primer pairs, (i.e., HV1A, HV1B, HV2A, 
and HV2B).  The amplified products were then sequenced using dye terminator 
chemistry, and analyzed using DHPLC as described above for Temperature-Modulated 
Heteroduplex Analysis.  In the resulting chromatograms, the presence of a single peak 
indicated sequence identity, whereas the presence of multiple peaks, or peaks with a 
distinct shoulder, indicated sequence non-identity.  All sequencing results were later 
compared with the results provided by the proficiency test manufacturer.
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Chapter Three:  Results and Discussion 
 
In the criminal justice system, the question of the admissibility of scientific 
evidence hinges on whether the evidence is reliable and is based on accurate and accepted 
scientific methods.  In order for the scientific analysis of an item of evidence to be 
admissible in a court of law, it must be tested and analyzed in a manner that is generally 
accepted by the scientific community.  This is based on the decision by the District of 
Columbia Court of Appeals in 1923, known as the Frye standard.  The Frye standard 
states that expert evidence was admissible in court if it was “sufficiently established to 
have gained general acceptance in the particular field in which it belongs” (Frye v. 
United States, 293 F. 1013 (D.C. Cir. (1923)).  In addition, the Supreme Court ruled in 
1993 in the case of Daubert vs. Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579 
(1993)) that the rule for “general acceptance” be broadened to allow for admission of 
scientific technologies and ensuing evidence that may be lacking in broad acceptance in 
the scientific literature.  Known as the Daubert standard, such admissibility requires that 
the technology rests on a sound scientific foothold; that the underlying scientific theory is 
valid and has been thoroughly tested; that it has representation in the peer review 
literature and that it has a known or potential error rate.  Thus, it is critically important in 
the current study for newly developed methods of forensic DNA analysis to undergo a 
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vigorous validation process.  The results presented in this study set the foundation for a 
complete validation of DHPLC as a tool to rapidly and accurately screen evidentiary 
mtDNA samples for sequence concordance/non-concordance. 
 
DHPLC Injection Reproducibility  
In order to demonstrate the reproducibility of DNA analysis by DHPLC and show 
that identical DNA samples independently injected will produce precise results, ten 
replicate injections were performed for DNA samples of two-component mixtures of 
each of four mtDNA amplicons commonly employed for forensic analyses. Amplicons 
consisting of database samples A7 and B7 (HV1A), D12 and E12 (HV1B), A5 and G4 
(HV2A), and F5 and D6 (HV2B) were combined at equimolar ratios, cross-hybridized 
and sequentially assayed by DHPLC under partially denaturing conditions. The resulting 
data indicate that DHPLC-based chromatographic fractionation of DNA molecules is 
highly reproducible for each amplicon. Assay-to-assay variability was found to be 
negligible across independent injections of amplicons from a single amplification 
reaction (Figure 9). Both the peak height (Figure 11) and retention times (Figure 12) were 
highly reproducible for each of the four hypervariable region amplicons as evidenced by 
the small standard deviations for each peak among the replicates (with an average 
coefficient of variation of 0.98% for peak height and 0.40% for retention time).  
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Figure 9:  Superimposed chromatograms for replicate assays of a 50:50 mixture of each 
four forensically relevant amplicons.  Illustrated is the assay-to-assay reproducibility 
across ten replicate injections from a single amplification reaction on a single DNASep® 
column.  Amplicon HV1A is a mixture of database samples A7 and B7, HV1B a mixture 
of D12 and E12 database samples, HV2A a mixture of A5 and G4 database samples, and 
HV2B a mixture of database samples F5 and D6.  See Figure 10 for the haplotypes 
relative to the rCRS for each database mixture, indicating which positions were 
mismatched in the heteroduplices. 
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Figure 10:  Haplotypes relative to the rCRS are shown for each of the four forensically 
relevant mtDNA hypervariable region amplicons used for the ten replicate injections 
from a single amplification reaction on a single DNASep® column as shown in Figure 9. 
Based on these haplotypes it is possible to identify those nucleotide positions that were 
mismatched in the heteroduplices.   
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Figure 11:  Peak heights (Mean±SD) for representative 50:50 mixtures for each of four 
forensically relevant mtDNA hypervariable region amplicons which resolve into either 
two or four chromatographic peaks. Illustrated for each amplicon is the assay-to-assay 
variability across ten sequential injections of DNA from a single amplification reaction 
that were fractionated by DHPLC on a single DNASep® column.  Amplicon HV1A is a 
mixture of database samples A7 and B7, HV1B a mixture of D12 and E12 database 
samples, HV2A a mixture of A5 and G4 database samples, and HV2B a mixture of 
database samples F5 and D6.  See Figure 10 for the haplotypes relative to the rCRS for 
each database mixture, indicating which positions were mismatched in the 
heteroduplices. 
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Figure 12:  Retention times (Mean±SD) for representative 50:50 mixtures for each of 
four forensically relevant mtDNA hypervariable region amplicons which resolve into 
either two or four chromatographic peaks.  Illustrated is the assay-to-assay variability 
across ten sequential injections of DNA from a single amplification reaction that were 
fractionated by DHPLC on a single DNASep® column. Amplicon HV1A is a mixture of 
database samples A7 and B7, HV1B a mixture of D12 and E12 database samples, HV2A 
a mixture of A5 and G4 database samples, and HV2B a mixture of database samples F5 
and D6.  See Figure 10 for the haplotypes relative to the rCRS for each database mixture, 
indicating which positions were mismatched in the heteroduplices. 
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DHPLC Amplification Reproducibility 
To demonstrate independent amplification reactions using replicate samples 
sequentially injected onto the DHPLC show precise and reproducible results, ten 
replicates of each of four mtDNA amplicons commonly employed for forensic analyses 
were separately amplified from samples in the study population. Amplicons consisting of 
database samples A7 and B7 (HV1A), D12 and E12 (HV1B), A5 and G4 (HV2A), and 
F5 and D6 (HV2B) were combined at equimolar ratios to form two-component mixtures, 
cross-hybridized and sequentially assayed by DHPLC under partially denaturing 
conditions. The resulting data indicate that DHPLC is highly reproducible for each 
amplicon. Assay-to-assay variability was found to be negligible among independent 
amplifications (Figure 13). Both the peak height (Figure 15) and retention times (Figure 
16) were highly reproducible for each of the four hypervariable region amplicons as 
evidenced by the small standard deviations for each peak among the replicates (with an 
average coefficient of variation of 7.1% for peak height and 0.32% for retention time). 
Variability in peak height relative to that observed in injection-to-injection 
reproducibility studies may be attributed to variability in the preparation and 
amplification efficiency of individual PCR replicates. 
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Figure 13:  Superimposed chromatograms for replicate assays of a 50:50 mixture of each 
four forensically relevant amplicons. Illustrated is the assay-to-assay reproducibility 
across ten replicate amplification reactions sequentially injected and fractionated by 
DHPLC on a single DNASep® column.  Amplicon HV1A is a mixture of database 
samples A7 and B7, HV1B a mixture of D12 and E12 database samples, HV2A a mixture 
of A5 and G4 database samples, and HV2B a mixture of database samples F5 and D6.  
See Figure 14 for the haplotypes relative to the rCRS for each database mixture, 
indicating which positions were mismatched in the heteroduplices. 
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Figure 14:  Haplotypes relative to the rCRS are shown for each of the four forensically 
relevant mtDNA hypervariable region amplicons used for the ten replicate amplification 
reactions that were sequentially injected and fractionated by DHPLC on a single 
DNASep® column as shown in Figure 13.  Based on these haplotypes it is possible to 
identify those nucleotide positions that were mismatched in the heteroduplices.   
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Figure 15:  Peak heights (Mean±SD) for representative 50:50 mixtures for each of four 
forensically relevant mtDNA hypervariable region amplicons which resolve into either 
two or four chromatographic peaks. Illustrated for each amplicon is the assay-to-assay 
variability across ten replicate amplification reactions sequentially injected and 
fractionated by DHPLC on a single DNASep® column.   Amplicon HV1A is a mixture of 
database samples A7 and B7, HV1B a mixture of D12 and E12 database samples, HV2A 
a mixture of A5 and G4 database samples, and HV2B a mixture of database samples F5 
and D6.  See Figure 14 for the haplotypes relative to the rCRS for each database mixture, 
indicating which positions were mismatched in the heteroduplices. 
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Figure 16:  Retention times (Mean±SD) for representative 50:50 mixtures for each of 
four forensically relevant mtDNA hypervariable region amplicons which resolve into 
either two or four chromatographic peaks.  Illustrated is the assay-to-assay variability 
across ten replicate amplification reactions sequentially injected and fractionated by 
DHPLC on a single DNASep® column.  Amplicon HV1A is a mixture of database 
samples A7 and B7, HV1B a mixture of D12 and E12 database samples, HV2A a mixture 
of A5 and G4 database samples, and HV2B a mixture of database samples F5 and D6.  
See Figure 14 for the haplotypes relative to the rCRS for each database mixture, 
indicating which positions were mismatched in the heteroduplices. 
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DHPLC DNASep® Column Variability 
To validate the reproducibility of DHPLC across multiple DHPLC DNASep® 
columns and demonstrate that different purchased columns produce similar results, ten 
two-component mixtures were prepared by mixing previously obtained database samples.  
Eight HV2B amplicon mixtures were created using database samples D3/E4, A1/B2, 
F5/A6, E10/H10, C8/G8, F7/F8, D12/G12, and C9/F9. Two HV2A amplicon mixtures 
were created using database samples G2/B3 and H8/D9.  These amplicon mixtures were 
sequentially injected onto each of ten different DNASep® columns under partially 
denaturing conditions. Again the results show that DHPLC assay results are highly 
reproducible even when comparing assays across multiple DHPLC DNASep® columns. 
An example of the observed column-to-column variability in chromatographic traces for 
a single two-component mixture is shown in Figure 17. Both the peak height and peak 
retention times (Figure 17) as well as the peak-to-peak interval (Figure 18) were found to 
be highly reproducible as evidenced by the negligible standard deviations (Figures 18 and 
19).  The average coefficient of variation was 15.1% for peak height and 0.5% for 
retention time. The peak-to-peak interval was calculated in this instance in order to 
determine the consistency of the profiles among different columns. 
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Figure 17:  Representative superimposed chromatograms for replicate assays of a 50:50 
mixture of amplicon HV2B for database samples C9 and F9. Illustrated is the assay-to-
assay reproducibility across ten DNASep® columns for the fractionation of a single two-
component mixture.  Haplotypes relative to the rCRS are also shown. Based on these 
haplotypes it is possible to identify those nucleotide positions that were mismatched in 
the heteroduplices.  
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Figure 19:  Peak-to-peak intervals (Mean±SD in min) calculated for each series of 
injections as a function of one peak to any other for two sets of HV2A amplicon mixtures 
and six sets of amplicon HV2B mixtures.  Database sample mixtures F7/F8 and C8/G8 
peak-to-peak intervals were not calculated due to only one peak produced.  See Figure 20 
for haplotype information from each amplicon mixture set of database samples. 
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Figure 20:  Haplotypes relative to the rCRS are shown for each of the ten HV2A or 
HV2B amplicon mixtures used for the ten replicate amplification reactions sequentially 
injected onto ten different DNASep® columns as shown in figure 19. Based on these 
haplotypes it is possible to identify those nucleotide positions that were mismatched in 
the heteroduplices. 
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DHPLC Assay Cross Contamination by DNA Carryover 
Sample cross contamination as a function of injection-to-injection carryover was 
evaluated by capture of zero-volume injections (i.e., DNA-free samples) following the 
injection of amplified PCR samples. In these assays, samples containing high quantities 
(approx. 550 ng) of an amplified 143bp DNA fragment (from a previously subcloned 
mtDNA coding region) were injected onto the DHPLC DNASep® column yielding a 
single peak with maximum absorbance at 3.82 ± 0.05min (Figure 21). This was followed 
by 5 zero-volume injections which were collected at the same time point where the DNA 
from the initial injection had eluted. Sample detection by UV absorbance revealed no 
evidence of DNA carryover in any of the zero-volume injections performed. However, 
the use of a DNA intercalating dye and fluorescence detection revealed DNA carryover 
in the initial zero-volume injections, ranging from 35pg - 125pg (Figure 22). Four 
subsequent zero-volume injections yielded 17pg, 14pg, 9pg and 8pg, respectively, as 
determined by DHPLC quantitation.  Eluent captured from the zero volume injections 
was evaporated by vacuum centrifugation, followed by dye terminator labeling. DNA 
sequencing reactions from the captured time period, however, yielded no detectable 
sequence (Figure 23). It is worth noting, that the amount of DNA injected onto the 
DNASep® column in this study is more than two-fold higher than the quantity of 
amplified mtDNA obtained from reference samples which typically yield 50ng - 200ng.  
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Figure 21:  Representative superimposed chromatograms for DHPLC analysis of an 
mtDNA amplicon (mt-Std-1) and five subsequent zero-volume injections (blanks). All 
blanks are coincident. Using UV detection, no indication of DNA carryover is evident 
between the initial high-abundance mt-Std-1sample and the five subsequent zero-volume 
injections.  
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Figure 22:  Representative superimposed chromatograms for DHPLC analysis of an 
mtDNA amplicon (mt-Std-1) and five subsequent zero-volume injections (blanks). Using 
fluorescence detection and scaled to a maximum y-axis value of 0.1 mV for enhanced 
DNA detection sensitivity, DNA carryover between the initial high-abundance mt-Std-1 
sample and the five subsequent zero-volume injections ranged from 35-125pg.  
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Figure 23:  Representative sequencing electropherogram generated by dideoxy-
terminator labeling of a captured zero volume injection. The top pane indicates the raw 
electrophoretic trace that was analyzed using the KB Basecaller software (Applied 
Biosystems) whereas the bottom pane indicates the data analyzed using the Sequencing 
Analysis Software v.5.1.1 (Applied Biosystems), which shows only stochastic 
electrophoretic “noise”.  The complete lack of any electrophoretic peaks above baseline 
demonstrates very low-level (if any) DNA carryover between the initial high-abundance 
mt-Std-1 sample and subsequent zero-volume injections (i.e., below the minimum 
threshold required for detection of DNA by direct DNA sequencing).   
  
Raw electrophoretic trace 
Analyzed data / noise 
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Screening of Evidentiary Samples – Validation of Comparative Sequence Analysis 
Using Known Samples 
One of the primary objectives of this study was to evaluate the potential utility of 
DHPLC as a means of screening amplified human mtDNA samples for sequence 
identity/non-identity in the context of a forensic laboratory. To thoroughly and 
realistically assess the reliability of DHPLC as a tool for comparative sequence analysis, 
the approach was tested on native mtDNA samples isolated from 95 research volunteers.  
Exclusive of length polymorphisms associated with the homopolymeric cytosine-
stretch in HV2, the 95 subjects in the study represented 83 distinct mtDNA haplotypes. 
Seventy-seven of these were unique within the study population. Of the 6 haplotypes 
which occurred more than once, the most common (263G, 315.1C) was observed 8 times, 
or approximately 8% of the total, which is comparable to the 7% frequency at which it 
occurs in the general population (Lutz-Bonengel et al., 2003).  The remaining 5 
haplotypes each occurred twice. Relative to the rCRS, the haplotypes represented in the 
current study encompass 84 polymorphisms in HV1 and 46 polymorphisms in HV2, 
including cytosine-stretch length polymorphisms.  
Based on pair-wise comparisons, individual haplotypes differed from each other 
at 0-22 positions (0-11 in HV1A; 0-13 in HV1B; 0-13 in HV2A; and 0-12 in HV2B). On 
average, there were 8.71 positional differences between haplotypes. In toto, the study 
population encompassed a broad diversity of haplotypes and thus was well suited for 
evaluating the utility of DHPLC for the accurate detection of sequence polymorphisms 
 63 
throughout the mtDNA control region. This is essential for the validation of DHPLC as a 
tool for comparative sequence analysis.  
A total of 920 pair-wise combinations of amplicons from the 95 individuals in this 
study were prepared, denatured and allowed to gradually re-anneal. Of these, 72 (22 
HV1A, 8 HV1B, 17 HV2A, and 25 HV2B mixtures) represented combinations of 
amplicons that were from different individuals but which had identical DNA sequences. 
DHPLC analyses of these samples all produced clear chromatograms consisting of a 
single symmetrical homoduplex peak. This pattern is consistent with sequence identity 
and is 100% concordant with direct sequencing data for these amplicons.  
To assess the reliability of DHPLC to detect sequence non-identity, 849 
combinations of amplicons (209 HV1A, 222 HV1B, 213 HV2A, and 205 HV2B 
mixtures) which differed in sequence were assayed. These differences encompassed a 
broad diversity of polymorphisms distributed throughout the HV1 and HV2 regions 
including transitions, transversions, insertions and deletions (Table 3). Positional 
differences were located centrally as well as near the termini of amplicons and 
encompassed regions of varying GC richness, ranging from approximately 15-80% GC 
content. In all, the mixtures assayed in this study included sequence variants at 39, 62, 38 
and 30 different positions in HV1A, HV1B, HV2A and HV2B, respectively. The 
distribution of the variant positions and the frequency with which they were assayed is 
illustrated in Figure 24.  
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Table 3:  Sequence polymorphisms in the HV1 and HV2 regions assayed by DHPLC. 
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Figure 24:  A histogram showing the distribution of nucleotide positions within HV1A, 
HV1B, HV2A and HV2B amplicons and the number of times that sequence 
polymorphisms at each position were assayed by DHPLC. The polymorphisms assayed 
are broadly distributed throughout both GC and AT rich regions as illustrated by the light 
gray line which indicates %GC content across each fragment, as measured by a rolling 
10bp average. 
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Using the aforementioned initial assay temperature for each mtDNA amplicon, 
DHPLC analyses correctly indicated the presence of a mixture of non-identical amplicons 
in 836 of the combinations tested (209 HV1A, 222 HV1B, 203 HV2A, and 202 HV2B). 
The remaining 13 mixtures of non-identical amplicons (10 HV2A and 3 HV2B) yielded 
chromatographic traces with a single eluent peak, a result erroneously suggesting 
sequence identity. Careful examination of the non-identical amplicon mixtures which 
were not detected by DHPLC reveals that these aberrant results are limited to a very 
small number of challenging positions. Specifically, it was not possible to detect non-
identical combinations of HV2A amplicons that differ only at positions 72 or 73. Taken 
together, these two positions account for all of the undetected non-identical mixtures 
involving HV2A amplicons.  
In HV2B, DHPLC was not able to detect non-identical combinations of amplicons 
that differed only at position 295. This position lies in a narrow stretch of sequence 
immediately adjacent to a large GC-rich region. Given the thermodynamic stability of 
this region, a single base mismatch may not sufficiently destabilize the surrounding helix 
such that an early eluting peak can be discerned. This is a postulate supported by the 
observation that mixtures of amplicons that possess an additional mismatch in this same 
region are readily detected.  
An inverse relationship was generally observed between the number of positional 
differences associated with a given pair of non-identical amplicons and the relative 
heights of the hetero- versus homoduplex peak(s). The height and retention time of a 
heteroduplex peak is a function of the stability and base sequence of the helix. The more 
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stable a heteroduplex, the more readily it should form relative to the competing 
homoduplices and thus the greater its peak height (indicative of quantity) on the DHPLC 
chromatograms. The corollary of this is that the formation of less stable helices is less 
favored and should be associated with smaller and earlier-eluting peaks on the DHPLC 
chromatograms. In theory, this could compromise the ability of DHPLC to detect, as non-
identical, some combinations of amplicons that differ at a large numbers of positions. In 
the current study, however, no examples of such “heteroduplex dropout” were observed. 
 
Screening of Evidentiary Samples – Forensic Validation  
Another primary objective of this study was to evaluate the potential utility of 
DHPLC as a means of screening amplified human mtDNA samples for sequence 
identity/non-identity using samples commonly seen in a forensic laboratory. To 
thoroughly and realistically assess the reliability of DHPLC as a tool for comparative 
sequence analysis, the approach was tested on mtDNA samples isolated from both 
database samples and a variety of sample types taken from 16 individuals, representing 
typical sample types present in forensic examinations. These included bloodstains 
(designated by the letter B) buccal swabs (designated by the letter S), hairs (designated 
by the letter H), vaginal swabs (designated by the letter V), semen swabs (designated by 
the letter M), saliva swabs (designated by the letter A) and a bone sample (designated by 
the letter N). To forensically validate the reliability of DHPLC to detect the presence of 
sequence variants between different mtDNA amplicons, 4x4 matrices of reference and 
questioned samples were created to show the varying steps in the process of data 
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evaluation (Figure 25). The assay components of each 4x4 matrix include an individual  
“PCR check”  assay to indicate whether the amplification product was of appropriate 
quantity, the “Denatured Control” assay to demonstrate that the samples were single 
source and did not contain a mixture (including heteroplasmy), and finally the two-
component “Mixed Sample” assays indicating sequence identity/non-identity.  Also 
included with the 4x4 matrix is a diagram with the haplotypes relative to the rCRS, from 
which it is possible to determine which positions were mismatched in each of the 
heteroduplices.  
Prior to each sequence identity/non-identity assay, amplified products were 
assayed by DHPLC under non-denaturing conditions in order to determine the quantity of 
amplified DNA, as visualized by the PCR Check peak. The samples were then denatured, 
slowly allowed to reanneal, and assayed by DHPLC under partially denaturing conditions 
in order to check for mixtures (e.g., heteroplasmy); as seen by the Denatured Control 
peak.  The quantity of DNA for each sample that was to be mixed was standardized to 5 
ng/μl to facilitate the generation of 50:50 equimolar mixtures. After cross-hybridization, 
mixtures were assayed by DHPLC under partially denaturing conditions to detect 
sequence identity/non-identity.  The presence of early eluting peaks or shoulders was 
taken as evidence of sequence non-identity and the results were compared to previously 
determined sequences for each of the four amplicons (HV1A, HV1B, HV2A and HV2B).  
In all, 20 separate 4x4 matrices were created, each consisting of 6 sequence identity/non-
identity assays for a total of 120 individual assays.  Of these assays, there were 74 base 
pairs differences total over the four amplicons, and encompassed a broad diversity of 
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polymorphisms.  Consistent with the results reported here in section 5 using known 
samples, in almost every instance the correct conclusion was made (i.e., inclusion vs. 
exclusion); (Figure 25). In only four assays was DHPLC not able to detect non-identical 
combinations of amplicons, indicating a success rate of 96.7%.  Here, DHPLC was not 
able to detect combinations of amplicons that differed only at position 73 in HV2A.  This 
was not unexpected since the sequence difference between these amplicons (73G vs. 
73A) was immediately adjacent to a short GC-rich region. The thermodynamic stability 
of this region is an intrinsic feature of the HV2A amplicon which interferes with the 
detection of base changes at position 73.  Figures 26-28 show additional representative 
examples of 4x4 matrices.  
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Figure 25:  Representative 4x4 matrix of DHPLC results for amplicon HV2A, samples 3B and 3S (database 
sample D9) and 4B and 4S (database sample E6). Green chromatograms represent PCR controls to show that the 
amplification worked and to allow determination of the quantity of DNA present in the sample (5μl injections, 
non-denaturing conditions), red chromatograms represent denatured controls  to show whether or not the sample 
itself is a potential mixture (including heteroplasmy); (5μl injections, partially denaturing conditions) and blue 
chromatograms represent sequence identity / non-identity assays which can be used to detect the presence of a 
mixture (8μl injections, partially denaturing conditions). Single peaks are consistent with sequence identity 
whereas multiple peaks or shoulders are consistent with sequence non-identity. 
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Figure 26:  Representative 4x4 matrix of DHPLC results for amplicon HV2B samples 1B and 1S (database 
sample H8) and 2B and 2S (new sample CE). Green chromatograms represent PCR controls to show that the 
amplification worked and to allow determination of the quantity of DNA present in the sample (5μl injections, 
non-denaturing conditions), red chromatograms represent denatured controls  to show whether or not the sample 
itself is a potential mixture (including heteroplasmy); (5μl injections, partially denaturing conditions) and blue 
chromatograms represent sequence identity / non-identity assays which can be used to detect the presence of a 
mixture (8μl injections, partially denaturing conditions). Single peaks are consistent with sequence identity 
whereas multiple peaks or shoulders are consistent with sequence non-identity. 
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Figure 27:  Representative 4x4 matrix of DHPLC results for amplicon HV1A, samples 3B and 3S 
(database sample D9) and 4B and 4S (database sample E6). Green chromatograms represent PCR controls 
to show that the amplification worked and to allow determination of the quantity of DNA present in the 
sample (5μl injections, non-denaturing conditions), red chromatograms represent denatured controls  to 
show whether or not the sample itself is a potential mixture (including heteroplasmy); (5μl injections, 
partially denaturing conditions) and blue chromatograms represent sequence identity / non-identity assays 
which can be used to detect the presence of a mixture (8μl injections, partially denaturing conditions). 
Single peaks are consistent with sequence identity whereas multiple peaks or shoulders are consistent with 
sequence non-identity. 
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Figure 28:  Representative 4x4 matrix of DHPLC results for amplicon HV1B, samples 5S and 5H (database 
sample H1) and 6H and 6S (database sample H7). Green chromatograms represent PCR controls to show that the 
amplification worked and to allow determination of the quantity of DNA present in the sample (5μl injections, 
non-denaturing conditions), red chromatograms represent denatured controls  to show whether or not the sample 
itself is a potential mixture (including heteroplasmy); (5μl injections, partially denaturing conditions) and blue 
chromatograms represent sequence identity / non-identity assays which can be used to detect the presence of a 
mixture (8μl injections, partially denaturing conditions). Single peaks are consistent with sequence identity 
whereas multiple peaks or shoulders are consistent with sequence non-identity. 
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Proficiency Test - Mixture Detection Results 
All DNA analysts employed in accredited forensic laboratories must undergo an 
external proficiency test twice a year per the Quality Assurance Standards for Forensic 
DNA Testing Laboratories guidelines.  Proficiency tests are a quality assurance tool used 
to determine analyst performance, verify standard operation procedures, and fulfill 
accreditation requirements.  These tests are administered by an external company, and 
consist of both “known” and “unknown” samples.  All of the samples present in the kit 
are processed by the analyst using standard protocols, and DNA profiles and/or mtDNA 
haplotypes are determined.  The tests are then scored by the external party on a pass/fail 
basis.   
To establish the accuracy of DHPLC in its ability to accurately screen for 
sequence identity/non-identity among authentic proficiency test samples given to forensic 
laboratories, a commercial kit was purchased from Orchid Cellmark (Dayton, OH).  This 
“DNA Mixture” kit comprised five samples:  three bloodstain reference FTA cards 
(sample names provided in kit as VB, S1B, and S2B), one bloodstained evidence FTA 
card (sample name CB), and one mixed evidence swab (sample name CS).   
Each proficiency test sample to be assayed for sequence identity/non-identity was 
denatured, slowly allowed to reanneal, and assayed by DHPLC under partially denaturing 
conditions. A mixture was detected for the HV1B amplicon of sample CS (mixed 
evidence swab). This was determined by visual detection of two peaks instead of one 
(Figure 29). Sample CS was subsequently sequenced, and clearly showed a mixed (T/C) 
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position at 16218 (Figure 30). This was the only mixed base position that was detected 
throughout the HV1 and HV2 regions using normal sequencing protocols.  
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Figure 29:  Chromatograms generated by DHPLC under partially denaturing conditions 
representing 5μl injections of individual samples (HV1B amplicon) that had been heat 
denatured and allowed to slowly reanneal (i.e., a Denatured Control). The single peaks on 
chromatograms 1, 3, 4, 5 indicate a single contributor; the multiple peaks/shoulder on 
chromatogram 2 indicates more than one contributor. These results were as expected as 
sample CS is a known mixed sample provided in the proficiency test kit. 
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Figure 30:  Representative sequencing electropherogram of mixed proficiency sample 
CS indicating a T/C mixture at position 16218 in the HV1B amplicon.  This position is 
the only detected mixed position throughout the HV1 and HV2 regions of this and all 
other proficiency test samples.    Dye terminator sequencing employed ABI BigDye v1.1 
chemistry on an ABI 310 sequencing platform. 
 
  
16218 
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Proficiency Test - Screening Results 
The five samples present in the proficiency test (reference samples VB, S1B, and 
S2B; evidence samples CB and CS) to be assayed in sequence identity / non-identity 
screening tests were amplified in all four HV1A, HV1B, HV2A, and HV2B regions, 
standardized to 3 ng/μl, mixed with each other at a 50:50 equimolar ratio, denatured and 
allowed to slowly reanneal, and assayed by DHPLC under partially denaturing 
conditions. A 5x5 matrix for each amplicon was created (Figure 31) due to comparison of 
five samples instead of four as previously described, and DHPLC results were compared 
to the sequencing results for each of the four amplicons (HV1A, HV1B, HV2A, and 
HV2B) to determine screening accuracy. In each instance, the correct conclusion (i.e. 
inclusion vs. exclusion) was made. These results were consistent with the DNA 
sequencing results for the same sample as is illustrated in Figure 32.   
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Figure 31:  Representative 5x5 matrix of DHPLC results for amplicon HV2A, for all proficiency samples. 
Green chromatograms represent PCR controls to show that the amplification worked as well and to allow 
determination of the quantity of DNA present in the sample (5μl injections, non-denaturing conditions), red 
chromatograms represent denatured controls  to show whether or not the sample itself is a potential mixture 
(including heteroplasmy); (5μl injections, partially denaturing conditions) and blue chromatograms 
represent sequence identity / non-identity assays which can be used to detect the presence of a mixture (8μl 
injections, partially denaturing conditions). Single peaks are consistent with sequence identity whereas 
multiple peaks or shoulders are consistent with sequence non-identity.  See Figure 32 for HV2A haplotype 
results for each sample in the proficiency test kit. 
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Figure 32:  mtDNA haplotyping results for amplicon HV2A of the five components of 
the proficiency test. Four out of the five samples exhibit sequence identity in HV2A, the 
exception being sample S1B. This is fully concordant with the results of the pair-wise 
sequence identity/non-identity assays which can be used to detect the presence of a 
mixture presented in Figure 31.   
 
 
 
 81 
 
 
 
Chapter Four:  Conclusions 
 
The results of this study have demonstrated that DHPLC analysis of pair-wise 
combinations of identical mtDNA amplicons both accurately and reliably produce a 
single chromatographic peak consistent with sequence identity. These results were 100% 
concordant with DNA sequence data. Conversely, in pair-wise combinations of non-
identical amplicons, DHPLC successfully detects a diversity of sequence differences 
throughout the HV1 and HV2 regions. These differences, which include a wide variety of 
base substitutions as well as insertions/deletions, are typically indicated by the presence 
of more than a single peak in the resulting chromatogram.  DHPLC results are 
reproducible, and cross contamination is not detectable.  As such, DHPLC may have 
significant forensic utility in several areas. These include a presumptive test of mtDNA 
identity between known and questioned samples and a screening test for mixed samples 
prior to direct sequencing. These results provide direct support for hypothesis 1:   
 
1. It was hypothesized that developmental validation of DHPLC will 
support its use as a tool for rapid and accurate comparative 
mtDNA sequence analysis.  This will make it possible to rapidly 
and cost effectively identify putative matches between questioned 
and known samples without laborious DNA sequencing. 
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Although DHPLC is not a replacement for direct sequencing of mtDNA, it does 
offer some advantages as a potential screening tool. First, the assay is relatively simple 
and fast. It uses raw PCR products thereby avoiding the time and expense associated with 
amplicon cleanup. Following cross-hybridization, each assay takes only seven minutes to 
run and interpretation of the results is straightforward. DHPLC provides a comprehensive 
assessment of sequence identity across an entire amplicon without the often challenging 
task of trying to obtain quality base sequence information immediately adjacent to primer 
binding sites.   
Compared to alternative mtDNA screening strategies based on oligonucleotide 
probes or linear arrays, DHPLC consumes less DNA and is not limited by the need to 
design probes for the detection of known mutations at predetermined polymorphic sites. 
This reduces the potential for false inclusions and eliminates the need to design custom 
probes for unique or rare sequence variants. Similarly, DHPLC assays are not subject to 
the “null” or “blank” results that arise when hybridization of the target sequence is 
impeded by other nearby polymorphisms. On the contrary, additional sequence variants 
typically make it easier to detect sequence non-identity between two amplicons.  
While DHPLC circumvents many of the limitations of alternate approaches to 
mtDNA screening, it is important to consider very carefully the types of samples for 
which such an approach might be indicated. Within an mtDNA sequencing laboratory, 
the results of the current study indicate that screening by DHPLC makes it possible to 
detect samples that contain mixtures of non-identical amplicons immediately after PCR 
amplification and without having to sequence them. For both heteroplasmic and 
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situational mixtures characterized by a secondary/minor source contributor, this approach 
allows the analyst to identify potentially challenging samples and mark them for “special 
handling” – whether that be the use of alternate sequencing primers to avoid C-stretch 
polymorphisms or the application of emerging technologies for resolving mixed samples 
(Danielson et al., 2005; Danielson et al., 2007). These results provide direct support for 
hypothesis 2: 
2. It was hypothesized that the developmental validation of DHPLC 
will allow it to act as a tool for identifying minor source 
components from mixed DNA samples.  This will facilitate the 
analysis of samples that yield low quality data when analyzed 
using current methods. 
 
It has been reasonably argued by experienced practitioners in the field that it is 
best to avoid using an mtDNA screening method on limited or irreplaceable evidentiary 
material (Melton et al., 2006; Divne et al., 2005). The results of the current study support 
the use of a presumptive DHPLC screen for mtDNA sequence identity. In addition, the 
results indicate that DHPLC can serve as a useful tool for investigators in special 
situations such as the investigation of property crimes. The limited budgets of many law 
enforcement agencies make it extremely difficult for investigators to justify the expense 
of mtDNA testing in the majority of criminal offences; particularly when there is no 
assurance a priori that the test results will necessarily advance an investigation. A 
presumptive screen for sequence identity between a suspect and an item of evidence, 
however, could provide sufficient justification to submit the sample for confirmatory 
analysis by direct sequencing. The results of the current study have demonstrated that 
such screening can help to readily eliminate from consideration such non-probative 
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samples as hairs consistent with a victim instead of a potential suspect. In short, this 
could help investigators to focus their efforts on the most probative samples and thereby 
maximize the efficient use of investigative resources.  Taken together, these results 
provide direct support for hypothesis 3: 
3. It is hypothesized that implementation of DHPLC analysis of 
mtDNA reference and evidentiary samples for casework will make 
it possible for law enforcement agencies to obtain potentially 
useful genetic data from samples that would not otherwise be 
amenable to analysis.   
 
 Employing a presumptive test of mtDNA sequence identity in the manner 
described above will also shift the process of DNA extraction from the dedicated mtDNA 
sequencing laboratory to the local law enforcement laboratory. This necessitates that 
additional consideration be given to the handling of these samples. The presence of 
evidentiary material with large quantities of mtDNA (e.g., blood, saliva and seminal 
fluids, etc.) in local laboratories can pose a significant risk of cross contamination. 
Accordingly, an mtDNA sequencing laboratory accepting a DNA extract for analysis 
would almost certainly require the submission of a co-extracted reagent blank control that 
could be tested to detect the presence of spurious mtDNA contamination. Similarly, the 
submission of amplified PCR products for direct sequencing would also need to be 
accompanied by the appropriate positive and negative PCR controls for quality control 
purposes.  
Forensic laboratory implementation of a commercial DHPLC analysis system can 
be achieved with minimal training and a maximum equipment cost of just over $135,000. 
The $0.50/run operating cost for DHPLC analyses is considerably less than that for 
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alternative approaches. Depending on the nature of casework being analyzed and level of 
throughput, the acquisition of a DHPLC system may be a fiscally viable option for some 
forensic laboratories as is already the case in the molecular diagnostics arena. 
In summary, the current study has demonstrated the potential utility of DHPLC-
based analysis for the economical and accurate screening of the HV1 and HV2 regions of 
mtDNA for sequence identity/non-identity. In a forensic case-working context, this 
approach to mtDNA sequence analysis can assist analysts by rapidly identifying 
potentially challenging mixed samples prior to direct sequencing. As a presumptive test 
for sequence identity, DHPLC makes it possible to screen for items of evidence that are 
potentially probative to an investigation, thereby saving the investigating agency 
significant funds.  
 
Future Directions 
Ongoing research will need to focus on the development of DHPLC-based 
approaches to resolving mtDNA mixtures and the subsequent validation of the method in 
accordance with guidelines of the Scientific Working Group on DNA Analysis Methods, 
the European DNA Profiling Group and the International Society for Forensic Genetics.  
This further validation to satisfy both Frye and Daubert standards would include 
performing DHPLC analysis as described in this study on samples that are from 
adjudicated cases, (i.e. those from forensic cases that have already been closed).  These 
samples would demonstrate that the methods outlined can handle real casework 
situations.  Also, non-human studies would need to be performed to show that other 
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biological materials using the methods discussed do not interfere with the ability to 
obtain reliable results.  Additional samples which contain minimal amounts of DNA 
should also be analyzed using the methods outlined in this paper, to show any potential 
stochastic effects that may occur during the PCR process or poor sensitivity during 
DHPLC detection.  All the experiments performed that are part of the validation study 
should also be made part of inter-laboratory studies to demonstrate that the methods used 
in one’s laboratory are reproducible in another laboratory.  These supplementary 
experiments should be shared with the scientific community through peer-reviewed 
publications in the professional literature.  
Additional research, such as more extensive studies using heteroplasmic samples 
encompassing a broader range of mutations, should also be performed.  In addition, the 
use of smaller amplicons currently used by the Armed Forces DNA Identification 
Laboratory (AFDIL) known as “mini-primer sets” could be investigated.  These mini-
primer sets range in size from 126-170 bp, and divide each hypervariable region into four 
segments instead of two, consisting of eight overlapping amplicons instead of the typical 
four.  Mini-primer sets are used with highly degraded DNA samples to enable greater 
recovery of overlapping sequence data of the HV1 and HV2 regions, due to their smaller 
target amplicon size.  This continuing research may further increase the forensic utility of 
DHPLC, increasing the types of samples that can be accurately screened.  Also, following 
the complete validation of forensic mtDNA analysis by DHPLC, standard operating 
procedures will need to be finalized, training manuals and quality assurance documents 
will need to be written, and individual laboratories will need to undergo additional 
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accreditation by the American Society of Crime Laboratory Directors Lab Accreditation 
Board (ASCLD-LAB).  Once accreditation is achieved by the laboratory, full 
implementation of the procedures outlined in this study can be implemented in actual 
forensic casework.  
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